
|Articles|June 1, 2001
Bexarotene safe treatment for early-stage CTCL
Washington - Bexarotene gel appears to be an effective and well-tolerated monotherapy when used as first-line treatment for early-stage cutaneous T-cell lymphoma, Madeleine Duvic, M.D., reported at the annual meeting of the American Academy of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Eli Lilly Trial Shows Superior Outcomes With Ixekizumab and Tirzepatide in Patients With PsA and Obesity
2
Phase 2a Evaluation of Dual OX40L/TNFα Antibody Begins in HS
3
Q&A: Adelle Walker on How Functional Wellness is Redefining Aesthetic Dermatology in 2026
4
FDA Feedback Supports BLA Pathway for Sonelokimab in HS
5


















